Recombinant
RabMAb

Recombinant Anti-MEK1 (phospho S298) antibody [EPR3338] - BSA and Azide free (ab214445)

Overview

  • Product name
    Anti-MEK1 (phospho S298) antibody [EPR3338] - BSA and Azide free
    See all MEK1 primary antibodies
  • Description
    Rabbit monoclonal [EPR3338] to MEK1 (phospho S298) - BSA and Azide free
  • Host species
    Rabbit
  • Tested applications
    Suitable for: IHC-P, WB, IHC-Fr, ICC/IFmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A phospho specific peptide corresponding to residues surrounding serine 298 of Human MEK1.

  • Positive control
    • WB: HeLa cell lysates IHC-P: colonic carcinoma tissue ICC/IF: HeLa cells
  • General notes

    The formulation and the concentration of this product is compatible for metal-conjugation for mass cytometry (CyTOF®).

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab214445 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Detects a band of approximately 45 kDa (predicted molecular weight: 43 kDa).
IHC-Fr Use at an assay dependent concentration.
ICC/IF Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for Flow Cyt or IP.
  • Target

    • Function
      Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
    • Tissue specificity
      Widely expressed, with extremely low levels in brain.
    • Involvement in disease
      Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
    • Sequence similarities
      Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
      Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
    • Information by UniProt
    • Database links
    • Alternative names
      • Dual specificity mitogen activated protein kinase kinase 1 antibody
      • Dual specificity mitogen-activated protein kinase kinase 1 antibody
      • ERK activator kinase 1 antibody
      • MAP kinase kinase 1 antibody
      • MAP kinase/Erk kinase 1 antibody
      • MAP2K1 antibody
      • MAPK/ERK kinase 1 antibody
      • MAPKK 1 antibody
      • MAPKK1 antibody
      • MEK 1 antibody
      • Mek1 antibody
      • MEKK1 antibody
      • Mitogen activated protein kinase kinase 1 antibody
      • MKK 1 antibody
      • MKK1 antibody
      • MP2K1_HUMAN antibody
      • PRKMK1 antibody
      • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
      • Protein kinase mitogen activated, kinase 1 antibody
      see all

    Images

    • ab96379 staining MEK1 (phospho S298) in the NIH3T3  cell line from Mouse fibroblasts by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with paraformaldehyde and blocked with 10% serum for 60 minutes at 24°C. Samples were incubated with primary antibody (1/100) for 16 hours at 4°C. An Alexa Fluor®488-conjugated Donkey anti-rabbit polyclonal(1/500) was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379, at a 1/100 dilution, staining MEK1 in paraffin embedded Human colonic carcinoma tissue by Immunohistochemical analysis.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379, at a 1/100 dilution, staining MEK1 in HeLa cells by Immunofluorescent analysis.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 showing positive staining in Thyroid gland carcinoma tissue.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 showing positive staining in Glioma tissue.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 showing positive staining in Ovarian carcinoma tissue.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with CNQX (ab120017), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of CNQX, as described in literature.
      The cells were incubated at 37�C for 24h in media containing different concentrations of ab120017 (CNQX) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4�C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with CNQX disodium salt (ab120044), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of CNQX disodium salt, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120044 (CNQX disodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with NBQX disodium salt (ab120046), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of NBQX disodium salt, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120046 (NBQX disodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with DNQX disodium salt (ab120169), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of DNQX disodium salt, as described in literature.
      The cells were incubated at 37°C for 3h in media containing different concentrations of ab120169 (DNQX disodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-5-Chlorowillardiine (ab120062), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-5-Chlorowillardiine, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120062 ((S)-5-Chlorowillardiine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-5-Nitrowillardiine (ab120063), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-5-Nitrowillardiine, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120063 ((S)-5-Nitrowillardiine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (R,S)-AMPA (ab120130), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of(R,S)-AMPA, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120130 ((R,S)-AMPA) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-AMPA (ab120005), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-AMPA, as described in literature.
      The cells were incubated at 37°C for 6h in media containing different concentrations of ab120005 ((S)-AMPA) in water, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with GYKI 52466 (ab120336), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of GYKI 52466, as described in literature.
      The cells were incubated at 37°C for 1h in media containing different concentrations of ab120336 (GYKI 52466) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with NBQX (ab120045), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of NBQX, as described in literature.
      The cells were incubated at 37°C for 1h in media containing different concentrations of ab120045 (NBQX) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with DNQX (ab120018), by ICC/IF. Decrease in MEK1 (phospho S298) expression correlates with increased concentration of DNQX, as described in literature.
      The cells were incubated at 37°C for 1h in media containing different concentrations of ab120018 (DNQX) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    • ab96379 staining MEK1 (phospho S298) in SK-N-SH cells treated with (S)-Williardine (ab120040), by ICC/IF. Increase in MEK1 (phospho S298) expression correlates with increased concentration of (S)-Williardine, as described in literature.
      The cells were incubated at 37°C for 6h in media containing different concentrations of ab120040 ((S)-Williardine) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab96379 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab96379).

    References

    ab214445 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab214445.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up